MMED (NASDAQ:MMED) Now Covered by Analysts at William Blair

Stock analysts at William Blair started coverage on shares of MMED (NASDAQ:MMED) in a note issued to investors on Tuesday. The firm set an “outperform” rating on the stock.

Several other equities research analysts have also weighed in on MMED. Wall Street Zen raised shares of MMED to a “hold” rating in a report on Saturday, March 14th. Evercore assumed coverage on MMED in a report on Tuesday. They issued an “outperform” rating and a $20.00 target price on the stock. Morgan Stanley began coverage on MMED in a research report on Tuesday. They issued an “overweight” rating and a $19.00 price objective for the company. BTIG Research started coverage on MMED in a report on Tuesday. They set a “buy” rating and a $25.00 target price on the stock. Finally, Citigroup initiated coverage on MMED in a research note on Tuesday. They issued a “buy” rating and a $23.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.33.

MMED Trading Down 0.8%

MMED stock opened at $14.35 on Tuesday. MMED has a one year low of $14.10 and a one year high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.